Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer-Reference-Cited by-同舟云学术

Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer

Published:2022-09 Issue: Volume:Volume 17 Page:4567-4578
ISSN:1178-2013
Container-title:International Journal of Nanomedicine
language:en
Short-container-title:IJN

Author:

Kosaka Yoshimasa,Saeki Toshiaki,Takano Toshimi,Aruga Tomoyuki,Yamashita Toshinari^ORCID,Masuda Norikazu^ORCID,Koibuchi Yukio,Osaki Akihiko,Watanabe Junichiro,Suzuki Ryu

Publisher

Informa UK Limited

Subject

Organic Chemistry,Drug Discovery,General Medicine,Biomaterials,Bioengineering,Biophysics,Pharmaceutical Science

Reference36 articles.

1. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity

2. Paclitaxel: a review of adverse toxicities and novel delivery strategies

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review;Nano TransMed;2024-12

2. A translational framework to DELIVER nanomedicines to the clinic;Nature Nanotechnology;2024-09-06

3. Characterization, stability, and skin application of astaxanthin particulates;AAPS Open;2024-09-02

4. Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials;Pharmaceutics;2024-08-06

5. Recent advances of polymeric nanoplatforms for cancer treatment: smart delivery systems (SDS), nanotheranostics and multidrug resistance (MDR) inhibition;Biomedical Materials;2023-11-27